Actividad eléctrica muscular en la marcha a distintas velocidades y en la carrera

En este estudio se analiza la actividad electromiográfica de los principales músculos de la extremidad inferior derecha: Glúteos Mayor y Medio, Recto Anterior y Vasto Interno del Cuádriceps, Isquiotibioperoneos, Gemelos y Tibial Anterior, al caminar en un tapiz rodante a distintas velocidades y en una carrera suave. Para dividir el ciclo de la marcha y la carrera en fases se utilizó un sistema de análisis tridimensional con dos cámaras de vídeo. La señal electromiográfica de cada una de estas fases se integró y se expresó en porcentaje de la actividad máxima isométrica de su músculo correspondiente. Los resultados obtenidos muestran que la participación muscular en la marcha lenta y normal es muy similar, sin embargo, en la marcha rápida aparecen aumentos importantes conservando el mismo patrón de actuación. En la carrera, no sólo existen actividades del triple de las halladas en la marcha a velocidad cómoda, sino que se modifica el patrón de actuación, presentando todos los músculos sus picos de actividad durante la fase de apoyo, momento en el que el centro de gravedad se lleva hacia delante sobre el miembro inferior

Actividad eléctrica muscular en la marcha a distintas velocidades y en la carrera

En este estudio se analiza la actividad electromiográfica de los principales músculos de la extremidad inferior derecha: Glúteos Mayor y Medio, Recto Anterior y Vasto Interno del Cuádriceps, Isquiotibioperoneos, Gemelos y Tibial Anterior, al caminar en un tapiz rodante a distintas velocidades y en una carrera suave. Para dividir el ciclo de la marcha y la carrera en fases se utilizó un sistema de análisis tridimensional con dos cámaras de vídeo. La señal electromiográfica de cada una de estas fases se integró y se expresó en porcentaje de la actividad máxima isométrica de su músculo correspondiente. Los resultados obtenidos muestran que la participación muscular en la marcha lenta y normal es muy similar, sin embargo, en la marcha rápida aparecen aumentos importantes conservando el mismo patrón de actuación. En la carrera, no sólo existen actividades del triple de las halladas en la marcha a velocidad cómoda, sino que se modifica el patrón de actuación, presentando todos los músculos sus picos de actividad durante la fase de apoyo, momento en el que el centro de gravedad se lleva hacia delante sobre el miembro inferior

Experimental transition probabilities in NII lines

Producción CientíficaThis work reports an extensive collection of 108 transition probabilities of NII lines in the visible spectral region, all of them measured in an emission experiment. Relative intensity measurements have been made on a pulsed discharge lamp and the absolute Aki values have been obtained by using the literature available data. Electron density and temperature range in this experiment from 0.2 to and from 17000 to 29000 K respectively. The first one has been simultaneously determined from two-wavelength interferometry and from the Stark broadening of HeI 471.3 nm, the second from Boltzmann-plot of NII lines and from NII/NI intensities ratios. The results are compared with the recent available literature.

Ministerio de Educación y Formación Profesional (grant PB-98-0356)Junta de Castilla y León (grant VA23-99

Evaluation of Clinical and Immunopathological Features of Different Infective Doses of Trypanosoma cruzi in Dogs during the Acute Phase

Infection with Trypanosoma cruzi is a major risk in Latin America, and dogs are believed to be good models for evaluating Chagas disease. Here, we evaluated the clinical and immunopathological alterations developed by mongrel dogs experimentally infected with different infective doses (2,000, 20,000, and 200,000 metacyclic trypomastigotes of Sylvio X10/4 strain kg−1 via intraperitoneal). Clinical and electrocardiographic parameters, as well as antibody production and pathologic lesions were evaluated. All three doses of this strain of T. cruzi induced a similar pattern of infection characterized by cardiac arrhythmias and severe and diffuse myocarditis. Specific anti-T. cruzi IgG indicated seroconversion by day 14 after infection, and IgG levels increased during the period of evaluation. Mortality was observed only in dogs infected with the medium or high parasite doses, but not in the group infected with a low dose of 2,000 parasites kg−1. Infection with a low dose of parasites provides an excellent nonlethal model to evaluate the immunopathology of the acute disease in dogs infected with the Sylvio X10/4 strain of T. cruzi

Loss of CIC promotes mitotic dysregulation and chromosome segregation defects

Background: CIC is a transcriptional repressor inactivated by loss-of-function mutations in several cancer types, including gliomas, lung cancers, and gastric adenocarcinomas. CIC alterations and/or loss of CIC activity have been associated with poorer outcomes and more aggressive phenotypes across cancer types, which is consistent with the notion that CIC functions as a tumour suppressor across a wide range of contexts. Results: Using mammalian cells lacking functional CIC, we found that CIC deficiency was associated with chromosome segregation (CS) defects, resulting in chromosomal instability and aneuploidy. These CS defects were associated with transcriptional dysregulation of spindle assembly checkpoint and cell cycle regulators. We also identified novel CIC interacting proteins, including core members of the SWI/SNF complex, and showed that they cooperatively regulated the expression of genes involved in cell cycle regulation. Finally, we showed that loss of CIC and ARID1A cooperatively increased CS defects and reduced cell viability. Conclusions: Our study ascribes a novel role to CIC as an important regulator of the cell cycle and demonstrates that loss of CIC can lead to chromosomal instability and aneuploidy in human and murine cells through defects in CS, providing insight into the underlying mechanisms of CIC's increasingly apparent role as a "pan-cancer" tumour suppressor

Spatial inter-comparison of Top-down emission inventories in European urban areas

This paper presents an inter-comparison of the main Top-down emission inventories currently used for air quality modelling studies at the European level. The comparison is developed for eleven European cities and compares the distribution of emissions of NOx, SO2, VOC and PPM2.5 from the road transport, residential combustion and industry sectors. The analysis shows that substantial differences in terms of total emissions, sectorial emission shares and spatial distribution exist between the datasets. The possible reasons in terms of downscaling approaches and choice of spatial proxies are analysed and recommendations are provided for each inventory in order to work towards the harmonisation of spatial downscaling and proxy calibration, in particular for policy purposes. The proposed methodology may be useful for the development of consistent and harmonised European-wide inventories with the aim of reducing the uncertainties in air quality modelling activities

Feature-based classifiers for somatic mutation detection in tumour–normal paired sequencing data

Motivation: The study of cancer genomes now routinely involves using next-generation sequencing technology (NGS) to profile tumours for single nucleotide variant (SNV) somatic mutations. However, surprisingly few published bioinformatics methods exist for the specific purpose of identifying somatic mutations from NGS data and existing tools are often inaccurate, yielding intolerably high false prediction rates. As such, the computational problem of accurately inferring somatic mutations from paired tumour/normal NGS data remains an unsolved challenge

SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors

Motivation: Next-generation sequencing (NGS) has enabled whole genome and transcriptome single nucleotide variant (SNV) discovery in cancer. NGS produces millions of short sequence reads that, once aligned to a reference genome sequence, can be interpreted for the presence of SNVs. Although tools exist for SNV discovery from NGS data, none are specifically suited to work with data from tumors, where altered ploidy and tumor cellularity impact the statistical expectations of SNV discovery

Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer

Aggressive variant prostate cancers (AVPC) are a clinically defined group of tumors of heterogeneous morphologies, characterized by poor patient survival and for which limited diagnostic and treatment options are currently available. We show that the cell surface 78-kDa glucose-regulated protein (GRP78), a receptor that binds to phage-display-selected ligands, such as the SNTRVAP motif, is a candidate target in AVPC. We report the presence and accessibility of this receptor in clinical specimens from index patients. We also demonstrate that human AVPC cells displaying GRP78 on their surface could be effectively targeted both in vitro and in vivo by SNTRVAP, which also enabled specific delivery of siRNA species to tumor xenografts in mice. Finally, we evaluated ligand-directed strategies based on SNTRVAP-displaying adeno-associated virus/phage (AAVP) particles in mice bearing MDA-PCa-118b, a patient-derived xenograft (PDX) of castration-resistant prostate cancer bone metastasis that we exploited as a model of AVPC. For theranostic (a merging of the terms therapeutic and diagnostic) studies, GRP78-targeting AAVP particles served to deliver the human Herpes simplex virus thymidine kinase type-1 (HSVtk) gene, which has a dual function as a molecular-genetic sensor/reporter and a cell suicide-inducing transgene. We observed specific and simultaneous PET imaging and treatment of tumors in this preclinical model of AVPC. Our findings demonstrate the feasibility of GPR78-targeting, ligand-directed theranostics for translational applications in AVPC

Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network

<p>Abstract</p> <p>Background</p> <p>Well-differentiated neuroendocrine carcinomas are highly vascularized and may be sensitive to drugs administered on a metronomic schedule that has shown antiangiogenic properties. A phase II study was designed to test the activity of protracted 5-fluorouracil (5FU) infusion plus long-acting release (LAR) octreotide in patients with neuroendocrine carcinoma.</p> <p>Methods</p> <p>Twenty-nine patients with metastatic or locally advanced well-differentiated neuroendocrine carcinoma were treated with protracted 5FU intravenous infusion (200 mg/m²daily) plus LAR octreotide (20 mg monthly). Patients were followed for toxicity, objective response, symptomatic and biochemical response, time to progression and survival.</p> <p>Results</p> <p>Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) criteria showed partial response in 7 (24.1%), stable disease in 20 (69.0%), and disease progression in 2 patients. Response did not significantly differ when patients were stratified by primary tumor site and proliferative activity. A biochemical (chromogranin A) response was observed in 12/25 assessable patients (48.0%); symptom relief was obtained in 9/15 symptomatic patients (60.0%). There was non significant decrease in circulating vascular epithelial growth factor (VEGF) over time. Median time to progression was 22.6 months (range, 2.7-68.5); median overall survival was not reached yet. Toxicity was mild and manageable.</p> <p>Conclusion</p> <p>Continuous/metronomic 5FU infusion plus LAR octreotide is well tolerated and shows activity in patients with well-differentiated neuroendocrine carcinoma. The potential synergism between metronomic chemotherapy and antiangiogenic drugs provides a rationale for exploring this association in the future.</p> <p>Trial registration</p> <p>NCT00953394</p